← Leaderboards
Natasha Ludwig-Barron
University Of California, San Francisco
$366,673
Attributed
$366,673
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $184.6K · FY2024–25$200K$150K$100K$50K$0
'24
'25
Funding mix
By agency
NIH$366,673 · 1
By mechanism
K01$366,673 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California, San Francisco
Same institution · by research overlap
- Julia Rose Adler-Milstein$10,805,039
- John Andrew Sauceda$6,156,698
- Meghan D Morris$5,979,123
- Erin Lynn Van Blarigan$5,308,724
- Ryan D. Hernandez$12,064,349
Others in their field
Other Rising Stars on “Acceptability And Feasibility”
- Schenita D. Randolph · Duke University$3,870,187
- Saeed Ahmed · Baylor College Of Medicine$3,372,206
- Tanya L Zakrison · University Of Chicago$3,254,872
- Czarina Navos Behrends · Weill Medical Coll Of Cornell Univ$3,156,884
- Keith Copelin Ferdinand · Tulane University Of Louisiana$2,797,027
- Heather Zierhut · University Of Minnesota$2,600,212
Research focus
Acceptability And FeasibilityAffectAids PreventionBehavioralBiobehaviorBiological MarkersCareerCareer DevelopmentCare OutcomesCaringCessation Of LifeCluster AnalysisCommunitiesCommunity PartnershipContinuity Of Patient CareData CollectionDesignDropsDrug UsageEducationEffectivenessEffectiveness TrialEpidemicAcceleration
Grant awards (3)
Proyecto Vida: Developing an HIV, HCV and opioid use MOST intervention for persons who inject drugs along the Texas-Mexico Border$134,302
K01 · FY2025 · DA · contact PI
Proyecto Vida: Developing an HIV, HCV and opioid use MOST intervention for persons who inject drugs along the Texas-Mexico Border$47,758
K01 · FY2025 · DA · contact PI
Proyecto Vida: Developing an HIV, HCV and opioid use MOST intervention for persons who inject drugs along the Texas-Mexico Border$184,613
K01 · FY2024 · DA · contact PI